Literature DB >> 11936844

The impact of insulin-like growth factor-1 on the pattern of cardiac elongation factor-2 variants in a model of overload.

Doris Jäger1, Ursula Müller-Werdan, Klaus Pönicke, Jürgen Holtz, Karl Werdan, Sylvana P Müller.   

Abstract

Because of its key role in proteosynthesis, the total content of elongation factor-2 (EF-2) and the distribution of six main EF-2 variants were investigated after Pseudomonas Exotoxin A catalyzed [37P]ADP-ribosylation using 1D-PAGE and isoelectric focusing (IEF) in a rat model of hemodynamic overload with variable degrees of cardiac hypertrophy: Chronic NO-synthase inhibition by L-NAME (N-omega-nitro-L-arginine-methyl-ester; 0.75 mg/ml drinking water) induced arterial hypertension without hypertrophy but myocardial apoptosis; additional treatment with IGF-1 (osmotic micropumps) did not modify hypertension but reduced apoptosis allowing moderate hypertrophy of the left ventricles. Total EF-2 did not significantly increase in rats with hemodynamic overload with or without IGF-1 supplementation. A positive correlation was found between an acidic EF-2 variant and apoptosis (p = 0.01). Hypertrophy under additional IGF-1 was combined with a shift of the EF-2 variants to basic subtypes (p < 0.01). This finding may be indicative of the trophic potency of IGF-1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11936844     DOI: 10.1023/a:1017982724938

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  42 in total

1.  Early changes of protein synthesis in myocardium and coronary arteries induced by NO synthase inhibition.

Authors:  M Gerová; O Pechánová; I Bernátová; M Kittová; M Juráni
Journal:  Physiol Res       Date:  1998       Impact factor: 1.881

2.  Effects of aging on the various steps of protein synthesis: fragmentation of elongation factor 2.

Authors:  J Parrado; M Bougria; A Ayala; A Castaño; A Machado
Journal:  Free Radic Biol Med       Date:  1999-02       Impact factor: 7.376

3.  Insulin-like growth factor I modulates induction of apoptotic signaling in H9C2 cardiac muscle cells.

Authors:  L Wang; W Ma; R Markovich; W L Lee; P H Wang
Journal:  Endocrinology       Date:  1998-03       Impact factor: 4.736

4.  Heterogeneity of cardiac rat and human elongation factor 2.

Authors:  D Jäger; C Seliger; N T Redpath; I Friedrich; R E Silber; K Pönicke; K Werdan; U Müller-Werdan
Journal:  Electrophoresis       Date:  2000-07       Impact factor: 3.535

5.  Long-term inhibition of NO synthase induces cardiac hypertrophy with a decrease in adrenergic innervation.

Authors:  M Gerová; B Hartmannová; S Dolezel; L Jezek
Journal:  Physiol Res       Date:  1996       Impact factor: 1.881

6.  Regulation of protein-synthesis elongation-factor-2 kinase by cAMP in adipocytes.

Authors:  T A Diggle; N T Redpath; K J Heesom; R M Denton
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

Review 7.  Cellular ADP-ribosylation of elongation factor 2.

Authors:  W J Iglewski
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

8.  Regulation of elongation factor-2 by multisite phosphorylation.

Authors:  N T Redpath; N T Price; K V Severinov; C G Proud
Journal:  Eur J Biochem       Date:  1993-04-15

9.  High-resolution one-dimensional polyacrylamide gel isoelectric focusing of various forms of elongation factor-2.

Authors:  N T Redpath
Journal:  Anal Biochem       Date:  1992-05-01       Impact factor: 3.365

10.  Role of elongation factor 2 in regulating peptide-chain elongation in the heart.

Authors:  T C Vary; A Nairn; C J Lynch
Journal:  Am J Physiol       Date:  1994-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.